NEUROTROPE, INC. (OTCMKTS:NTRPD) Files An 8-K Other EventsItem 8.01Other Events.
On September 5, 2018, Neurotrope, Inc. (the “Company”) announced a collaboration with The Nemours / Alfred I. duPont Hospital for Children (“Nemours”) to initiate a clinical trial in children with Fragile X Syndrome (“Fragile X”). The planned protocol for the trial will dose Fragile X patients between the ages of 8 and less than 18, using a dosing regimen similar to the dosing regimen used in the Company’s completed Phase 2 trial involving patients with Alzheimer’s disease. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior.
About NEUROTROPE, INC. (OTCMKTS:NTRPD)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.
